Regulatory requirements are always there in black and white. Prana has the options to circumvent those roadblocks. FDA is actually nice allowing Prana to complete several human trials first to collect supporting data. If Prana failed in commercializing PBT2 finally, they could only blame themselves.
Regulatory requirements are always there in black and white....
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.4¢ | 0.3¢ | $7.879K | 2.590M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 58 | 79758033 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 1157860 | 1 |
View Market Depth
| Last trade - 15.57pm 17/09/2024 (20 minute delay) ? |
| ATH (ASX) Chart |